Congestive Heart Failure (CHF) Market Report 2026

The congestive heart failure (chf) market size has grown strongly in recent years. It will grow from $17.1 billion in 2025 to $18.31 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to aging population growth, high prevalence of cardiovascular disease, limited outpatient monitoring options, frequent hospital readmissions, dependence on hospital-based care.

The congestive heart failure (chf) market size is expected to see strong growth in the next few years. It will grow to $23.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing heart failure prevalence, improved diagnostic accuracy, growth of homecare settings, rising adoption of guideline-based therapies, focus on reducing hospital readmissions. Major trends in the forecast period include rising adoption of combination drug therapies, shift toward home-based heart failure management, increasing focus on early diagnosis and monitoring, growth in chronic disease management programs, expansion of post-discharge care pathways.

The growing number of cardiovascular patients is expected to drive the expansion of the congestive heart failure (CHF) market in the coming years. Cardiovascular relates to the heart and blood vessels and their role in blood circulation and maintaining overall body health. The increase in cardiovascular patients is attributed to sedentary lifestyles, poor dietary habits, aging populations, and rapid urbanization, which together are raising the demand for advanced healthcare and treatment solutions. Congestive heart failure (CHF) supports cardiovascular patients by offering targeted therapies that enhance heart function, alleviate symptoms, and reduce the risk of complications, thereby improving patient outcomes and overall well-being. For example, in January 2023, according to the American College of Cardiology, a US-based nonprofit medical society, cardiovascular disease cases reached 19.8 million in 2022. In addition, Eastern Europe recorded the highest mortality rate, with 553 deaths per 100,000 people. As a result, the rising prevalence of cardiovascular patients is contributing to the growth of the congestive heart failure (CHF) market.

Companies operating in the congestive heart failure (CHF) market are increasingly concentrating on advanced innovations such as single intracoronary infusion therapies to deliver effective treatments that improve heart function and enhance the quality of life for patients with CHF. Single intracoronary infusion involves administering medication directly into the coronary artery, allowing precise targeting of the heart for conditions such as congestive heart failure. For instance, in January 2024, Bayer AG, a Germany-based pharmaceutical company, along with Asklepios Biopharmaceutical, Inc., a US-based biotechnology company, initiated the GenePHIT Phase II clinical trial for AB-1002, an investigational gene therapy designed to treat congestive heart failure (CHF). This approach applies gene therapy to target non-ischemic cardiomyopathy, presenting a potential advancement in CHF treatment through precision-based genetic solutions. The study is an adaptive, double-blind, placebo-controlled trial and is expected to enroll between 90 and 150 participants who have been medically stable for at least four weeks and exhibit a left ventricular ejection fraction ranging from 15% to 35%.

In October 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired V-Wave Ltd. for an undisclosed amount. This acquisition allows Johnson & Johnson to strengthen its MedTech portfolio in cardiovascular care, particularly in the area of heart failure, through the addition of the Ventura Interatrial Shunt technology. V-Wave Ltd. is an Israel-based company that specializes in developing innovative treatment solutions for patients with congestive heart failure.

Major companies operating in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, Novartis AG, Medtronic Plc, Canon Medical Systems Corporation, Jarvik Heart Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova Plc, Edwards Lifesciences Corporation, Getinge AB, MicroPort Scientific Corporation, Lepu Medical Technology Co Ltd, OSCOR Inc., Shree Pacetronix Ltd.

North America was the largest region in the congestive heart failure (CHF) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (chf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congestive heart failure (chf) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the congestive heart failure market by increasing costs of imported cardiovascular drugs, diagnostic devices, implantable monitoring equipment, and medical consumables. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported cardiac technologies, while Asia-Pacific faces increased costs for diagnostic and treatment equipment. These tariffs are raising treatment expenses. However, they are also supporting domestic pharmaceutical manufacturing, regional device production, and stronger local supply chains for chronic cardiac care.

The congestive heart failure (chf) market research report is one of a series of new reports that provides congestive heart failure (chf) market statistics, including congestive heart failure (chf) industry global market size, regional shares, competitors with a congestive heart failure (chf) market share, detailed congestive heart failure (chf) market segments, market trends and opportunities, and any further data you may need to thrive in the congestive heart failure (chf) industry. This congestive heart failure (chf) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Congestive heart failure (CHF) is a long-term and progressive condition in which the heart’s capacity to pump blood efficiently is reduced, resulting in fluid buildup in the lungs, heart, liver, and other areas of the body. This leads to symptoms such as shortness of breath, fatigue, swelling, and difficulty carrying out daily activities, ultimately affecting overall quality of life and requiring continuous medical care and treatment.

The primary types of congestive heart failure (CHF) include systolic heart failure, diastolic heart failure, left-sided heart failure, and right-sided heart failure. Systolic heart failure occurs when the heart muscle’s pumping ability is weakened, leading to insufficient blood circulation. Treatment options include medications and surgical interventions, supported by diagnostic methods such as electrocardiogram, echocardiogram, magnetic resonance imaging (MRI), stress tests, blood tests, and cardiac catheterization, along with other diagnostic approaches. These treatments are delivered through distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies, and are utilized by end users such as hospitals, specialty clinics, ambulatory surgical centers, and homecare settings.

The congestive heart failure (CHF) market consists of revenues earned by entities by providing cardiac treatment, hemodynamic monitoring, and therapeutic services. The market value includes the value of related goods such as diagnostic tools, monitoring devices, and support services. The congestive heart failure (CHF) market also includes sales of diagnostic tools, and testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.